Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025 BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150 million in potential milestone payments Additional details will be shared at BioNTech’s Innovation Series R&D Day event on 14 November 2024 MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.

收购为了支持BioNTech肿瘤学战略的全球实施，并为研究性PD-L1 x VEGF-A双特异性抗体BNT327/PM8002提供全面的全球权利，有可能取代目前的检查点抑制剂标准治疗实体瘤收购Biotheus，BioNTech旨在进一步加强其开发，制造和商业化下一代双特异性抗体和新型治疗组合的能力BioNTech和Biotheus计划在2024年底和2025年启动BNT327/PM8002的多项注册试验；将BNT327/PM8002评估为联合疗法的进一步临床试验计划于2024年和2025年开始，BioNTech将支付8亿美元收购100%的已发行股本，并支付高达1.5亿美元的潜在里程碑付款。其他细节将在2024年11月14日的BioNTech创新系列研发日活动上分享，德国美因茨，2024年11月13日（环球通讯社）——BioNTech SE（纳斯达克：BNTX，“BioNTech”）和Biotheus（“Biotheus”）今天宣布签署最终协议，收购Biotheus，Biotheus是一家临床阶段的生物技术公司，致力于发现和开发新型抗体，以满足患者未满足的医疗需求患有肿瘤或炎症性疾病。

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part of BioNTech’s oncology strategy, aimed at enhancing the company’s capabilities to research, develop and commercialize combination therapies using BNT327/PM8002.

通过此次收购，BioNTech将获得晚期临床资产BNT327/PM8002的全部全球权利，BNT327/PM8002是一种针对PD-L1和VEGF-A的研究性双特异性抗体。该交易是BioNTech肿瘤学战略的一部分，旨在增强公司使用BNT327/PM8002研究，开发和商业化联合疗法的能力。

Clinical trials with BNT327/PM8002 and the PD-(L)1 x VEGF bispecific class of drugs have demonstrated enco.

BNT327/PM8002和PD-（L）1 x VEGF双特异性药物的临床试验已经证明了enco。